BEDFORD, Mass.—Ocular Therapeutix Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye, has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), according to a recent announcement. Ocular Therapeutix’s addition to the NBI became effective Monday, Dec. 24. Ocular Therapeutix's first product, ReSure Sealant, is FDA-approved to seal corneal incisions following cataract surgery. Ocular Therapeutix is developing innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, according to the company’s recent announcement.

Ocular Therapeutix’s first commercial drug product, Dextenza, is FDA-approved for the treatment of ocular pain following ophthalmic surgery. OTX-TP (intracanalicular travoprost insert) is an intracanalicular insert in Phase 3 clinical development for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.

The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark. All securities in the Nasdaq Biotechnology Index are listed on the Nasdaq Global Market or the Nasdaq Global Select Market, and are expected to meet minimum market value and share volume requirements among other criteria.